Know Labs Expands Board of Directors
08 Novembre 2023 - 3:00PM
Business Wire
Appoints Three New Directors with Deep
Sector Expertise
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced the
appointment of three new members to the Company’s Board of
Directors. These appointments increase the number of Directors to
seven. Each new Director brings to the board extensive
sector-relevant experience with deep knowledge of the science and
the marketplace that is the focus of Know Labs. The new appointees
are John Cronin, Larry Ellingson and Tim Londergan.
John Cronin is the founder and CEO of ipCapital Group,
Inc., a leading global advisory company on intellectual property
strategy and monetization. Cronin began his career at IBM where he
was the sole inventor of breakthrough chip design technology that
became the company’s most valuable patent, generating $500 million
in revenue. He went on to create the IBM Patent Factory and grew
IBM’s patent portfolio from ninth to number one in the world. He
played a pivotal role in increasing IBM’s patent licensing revenue
from $30 million to over $2 billion a year. Cronin has been a
strategic advisor and consultant to Know Labs, supporting the
company’s expanding patent portfolio from 86 to 246 patents issued,
pending and in process over the last twelve months, increasing its
global leadership in the non-invasive blood glucose monitoring
category.
Larry Ellingson has been a member of Know Labs’ Medical
Advisory Board for the past four years. Ellingson’s insight and
global relationships have been instrumental in shaping Know Labs’
strategy and opening important doors in the diabetes industry.
Ellingson’s background includes 30 years with Eli Lilly where he
headed the multibillion-dollar annual revenue Diabetes Care
business unit. Ellingson has been an advocate for accessible and
affordable diagnosis and treatment through his activities with
diabetes focused non-profit organizations. Among his many
activities he has served as Chairman of the Board of the American
Diabetes Association and has been the Vice-Chairman of the Board of
the Diabetes Leadership Council for the last several years.
Tim Londergan is the founder and CEO of Tangibly, Inc.,
developer of the globe’s pre-eminent trade secret management
platform. Trade secrets are a key component of an IP asset base and
include the company’s proprietary algorithms. Londergan has a Ph.D.
in Chemistry and experience as a CEO and COO of technology
companies, including Lumera, Wavefront Venture Labs and Operem. He
spent several years as Head of Commercial Development at
Intellectual Ventures--a six-billion-dollar global intellectual
property fund. In that role he managed a project between
Intellectual Ventures and Know Labs to enhance Know Labs’ IP
portfolio. Recently, Londergan was named IAM 300 World’s Leading IP
Strategist 2023.
“We are fortunate to be able to attract to our board these
respected individuals whose areas of expertise are directly related
to the work we have underway,” said Ron Erickson, CEO and Chairman
at Know Labs. “Their insights will help us build upon the knowledge
and skills of our other board members and our own team as we refine
our technology, expand our IP asset base, work on strategic
collaboration opportunities, and prepare for submission and
hoped-for FDA clearance of our non-invasive blood glucose
monitoring device. We are thrilled to have John Cronin, Larry
Ellingson and Tim Londergan join our Board of Directors.”
For more information on Know Labs, visit www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
platform technology uses spectroscopy to direct electromagnetic
energy through a substance or material to capture a unique
molecular signature. The technology can be integrated into a
variety of wearable, mobile or bench-top form factors. This
patented and patent-pending technology makes it possible to
effectively identify and monitor analytes that could only
previously be performed by invasive and/or expensive and
time-consuming lab-based tests. The first application of the
technology will be in a product marketed as a non-invasive glucose
monitor. The device will provide the user with accessible and
affordable real-time information on blood glucose levels. This
product will require U.S. Food and Drug Administration clearance
prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108027345/en/
For Know Labs Media Inquiries Contact: Matter Health Abby
Mayo Knowlabs@matternow.com Ph. (617) 272-0592
Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co
Ph. (206) 629-6414
Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Mag 2023 a Mag 2024